AZmed, a French company specializing in AI-powered radiology software, has secured $16.2 million in investment capital. This funding round represents a significant milestone for the company as it continues to advance its solutions designed to enhance medical imaging diagnostics and support healthcare professionals.
The company addresses a critical and growing challenge in healthcare. Over the past decade, the number of medical imaging acts has doubled in OECD countries, while the specialist workforce capable of analyzing this increased volume has remained largely stagnant. AZmed's artificial intelligence technology, particularly for trauma and chest X-ray diagnostics, helps doctors save valuable time and allows them to dedicate more focus and resources to life-threatening examinations. Its deep learning solutions are engineered for seamless integration into existing medical workflows, ensuring ease of use without requiring changes to doctors' established habits.
AZmed differentiates itself by concentrating on high-volume, low-level exams, which significantly improves daily productivity and optimizes workflows for medical professionals. Its flagship product, Rayvolve, holds both CE-marked IIa and FDA-cleared status, underscoring its regulatory compliance and effectiveness. The company's solutions are currently deployed in over 2500 healthcare institutions, with more than 9000 doctors utilizing the technology daily across 55 countries and five continents, demonstrating its global reach and impact.
The newly raised capital is earmarked to support AZmed's ongoing growth initiatives, including the further development of its AI technologies and strategic expansion into new markets. This substantial investment will enable the company to scale its operations, enhance its product offerings, and continue its mission of assisting radiologists globally in managing increasing workloads.
AZmed remains dedicated to collaborating closely with medical professionals to shape the future of medical imaging, improve diagnostic efficiency, and ultimately contribute to better patient outcomes worldwide.
.png&w=3840&q=75)
